He got two rival drug giants to write checks into the same company. The trick was solving a problem they both hated.
A doctor writes a prescription. Then nothing happens. Coverage is unclear, prior authorization sits in a queue, the sample never ships, and the patient waits. Dan Cornwell built a company around that silence.
PrescriberPoint is an AI-enabled medication access platform, and Dan Cornwell is its founder and chief executive. The product is unglamorous on purpose. It pulls drug information, FDA label data, coverage checks, sample ordering and prior-authorization support into one place, so a clinician can get a patient on therapy without playing phone tag with three companies. The pitch, stripped down: the distance between a good intention and a completed transaction is a software problem.
That sounds simple until you look at who has to cooperate to make it work - pharmaceutical manufacturers, insurers and pharmacies, none of whom were built to share a screen. PrescriberPoint's job is to be the neutral counter where they meet. The platform reportedly reaches an estimated 70 to 90 percent of targeted prescribers through an omnichannel approach, then hands them tools that include agentic-AI support for the paperwork that usually stalls everything.
The company did not begin in a garage. It was spun out of Eli Lilly in collaboration with BCG Digital Ventures, the corporate-venture studio where Cornwell had been advising. That heritage matters: it is why a startup this young was taken seriously by the very incumbents it wanted to rewire.
Series Seed announced January 2023
Getting Lilly and Pfizer to back the same young company is a little like getting Coke and Pepsi to co-sign a lease. They compete on shelves every day. Yet both joined PrescriberPoint's seed round, alongside Adobe and Mastercard - a software giant and a payments network that, on paper, have nothing to do with prescribing.
The logic clicks once you see the platform as plumbing rather than a product anyone owns. Adobe brings the digital-experience layer. Mastercard brings the muscle of moving transactions across industries that don't normally talk. The drugmakers bring the reason it all matters. Cornwell's real feat was less technical than diplomatic: he framed a problem big enough that competitors would rather fund the fix together than each lose to it alone.
"We are on a mission to get patients on therapy more efficiently by connecting HCPs with the right resources at the right time."- Dan Cornwell, CEO, PrescriberPoint
Before PrescriberPoint, Cornwell ran IntelyCare, a Series C nurse-staffing marketplace where he served as CEO and CFO. Different industry, same shape of problem: a shift goes unfilled, a facility is short-staffed, and the matching breaks down at exactly the wrong moment. The fix, again, was a marketplace that closed the gap.
Trace the resume and the throughline holds. At BCG Digital Ventures he was a Senior Advisor helping invent, build and scale new businesses. He advised at antuit.ai, where AI met Fortune 1000 operations, and at Vantage Partners on strategy. Earlier he was EVP of Client Solutions at Exchange Solutions, did M&A and growth-strategy work at Monitor Deloitte, and started out as a marketing representative at IBM selling to financial institutions. He was also on the founding team of Blue Ivy Ventures, a fund built so Yale alumni could invest in Yale-led companies.
Read together, it is the career of someone allergic to broken handoffs - the moments when a system that should flow simply stops.
Cornwell did not arrive by the obvious door. He studied History at Yale - not biology, not computer science. He added an MBA in Finance from Wharton and a certificate in International Relations from Cambridge. It is a humanities-and-finance pedigree pointed at one of the most technical, regulated corners of the economy.
There is a quiet logic to it. Medication access is not really a chemistry problem; it is a coordination problem dressed up in clinical language. Knowing how institutions behave, how incentives bend, and how money actually moves may be better preparation than knowing how a molecule binds. A historian is trained to ask why a system ended up this broken before trying to fix it.
The aspiration is blunt: make starting a prescription feel less like filing a permit and more like flipping a switch. One place for the drug page, the coverage check, the sample order and the prior-auth grind - with AI doing the parts that used to eat an afternoon. If it works, the patient never sees the machinery. That invisibility is the point.
It is an audacious bet on cooperation in an industry that runs on competition. But Cornwell has already proven he can get adversaries to agree on at least one thing: the current way is broken, and someone should fix it.